abbott  global healthcare  research as hepatitis pushes us we won’t fail learn more focus on cybersecurity learn more the virus hunters a look into how abbott and our partners identify and track evolving strains of hiv hepatitis and other viruses learn more our mission help you live the best life you can play video at our healthiest anything is possible play video none accessibility learn more abbott bigfoot partner on diabetes care abbott and bigfoot biomedical have entered into an agreement to develop breakthrough diabetes technologies learn more abbott announces strong second quarter ahead of expectations through the first half of the year company raises guidance learn more why branded generics matter are all medicines created equal find out how abbott is meeting healthcare needs in emerging markets learn more more than a gut feeling abbott’s rachael buck explains how the gut microbiome plays a critical role in lifelong health none accessibility careers my role provides me with the opportunity to gain an understanding of all areas of the business which helps to steer me on a good path for my future at abbott richard quality engineer diabetes care   get inspired careers investors newsroom citizenship partners contact site map policies privacy policy terms  conditions true accessibility you are about to exit for another abbott country or region specific website please be aware that the website you have requested is intended for the residents of a particular country or countries as noted on that site as a result the site may contain information on pharmaceuticals medical devices and other products or uses of those products that are not approved in other countries or regions the website you have requested also may not be optimized for your specific screen size do you wish to continue and exit this website yesno accessibility you are about to exit the abbott family of websites for a rd party website links which take you out of abbott worldwide websites are not under the control of abbott and abbott is not responsible for the contents of any such site or any further links from such site abbott is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by abbott the website that you have requested also may not be optimized for your screen size do you wish to continue and exit this website yesno accessibility asset warning yesno our story  impax laboratories inc investor relations media center careers contact home our company our experience our divisions our company our story future directions leadership business development corporate responsibility facilities new cpsia product list home » our company » our story our story at impax laboratories we are following a growthoriented strategy to become a leader in the development manufacturing and marketing of specialty prescription pharmaceutical products strategic merger on december   global pharmaceutical corporation and privately held impax pharmaceuticals inc completed a reverse merger forming a new organization called impax laboratories inc the merger combined the advanced drug delivery systems developed by impax pharmaceuticals through its research and development capabilities with global pharmaceutical’s sales marketing and distribution capabilities drug applications the synergy created by the merger provided the foundation for the current and future success of the organization since  impax laboratories consistently files abbreviated new drug applications with the food and drug administration fda annually and has received tentative and final approval from the fda for numerous generic products we are also developing proprietary branded products for unmet needs in the treatment of central nervous system cns disorders we have one new drug application pending at the fda for the treatment of symptomatic parkinson’s disease marketing partnerships and business development where strategically appropriate the company has developed marketing partnerships to fully leverage its technology platform in order to maximize product revenues and profitability impax laboratories also has two marketing divisions of its own for its products its global pharmaceuticals division sells generic products while branded products are marketed through the impax pharmaceuticals division we are also pursuing generic and brand partnership and business development ma opportunities global pharmaceuticals is looking at opportunities to acquire products technologies or companies with strategic value mainly in the alternative dosage area such as injectables creams and ointments inhalers or patches impax pharmaceuticals is searching for external growth opportunities with a focus on neurology and psychiatry products related linksbusiness development pipelinewe consistently invest in generic and brand rd to create new pipeline opportunitieslearn more copyright   impax laboratories inc all rights reserved privacy policy legal notices purchase order terms and conditions sitemap generics division  impax laboratories inc investor relations media center careers contact home our company our experience our divisions our divisions generics division specialty pharma division home » our divisions » generics division impax generics our generics division view website impax has developed a portfolio of generic pharmaceuticals through the internal filing of abbreviated new drug applications andas and through partnerships on alternative dosage form products our generic product development strategy is based on a combination of speed to filing and a legal strategy primarily predicated upon noninfringement of established brand name pharmaceuticals we are focused on targeting highvalue solid oral and alternative dosage form andas that are difficult to develop and that bring sustainable profitability global’s multisource product line consists of a growing range of solid oral and alternative dosage form prescription pharmaceuticals distributed primarily through drug wholesalers distributors warehousing chains and managed healthcare organizations the organization continues to invest in order to provide the highest level of research and development manufacturing and customer service our quality assurance team works closely with our suppliers to ensure purity consistency and quality of products and we strive to bring value to our customers with innovative products in key therapeutic areas we have a dedicated team of experienced professionals handling customer orders and inquiries that work to not only meet the expectations of our customers but consistently deliver beyond expectations every member of our team is committed to the success and profitability of our customers we have set the highest standards for our products services and people and are proud of the organization we are building we develop manufacture sell and distribute generic pharmaceutical products primarily through three sales channels product sales channel for generic pharmaceutical prescription products we sell directly to wholesalers large retail drug chains mass merchandisers and mailorder pharmacies rx partner sales channel for generic prescription products sold through unrelated thirdparty pharmaceutical entities pursuant to alliance agreements otc partner sales channel for sales of generic pharmaceutical otc products sold through unrelated thirdparty pharmaceutical entities pursuant to alliance agreements product development strategy our generic product development strategy is based on two opportunities weve identified in the generic pharmaceutical marketplace controlledrelease generic products through our controlledrelease drug delivery technologies and formulation skills we develop bioequivalent versions of selected brand name pharmaceuticals controlledrelease pharmaceuticals generally have technically challenging drug delivery requirements we employ our proprietary processes and formulation expertise to develop products that reproduce the brand name product’s physiological characteristics but do not infringe upon the brand product’s patents specialty generic products products that present one or more competitive barriers to entry such as difficulty sourcing raw material complex formulation or development characteristics or special handling requirements our products we currently manufacture and market  generic pharmaceutical products which represent dosage variations of  different pharmaceutical compounds through our generics division another five of our generic pharmaceutical products representing dosage variations of two different pharmaceutical compounds are marketed by our alliance agreement partners our pipeline we currently have more than  abbreviated new drug applications anda pending at the fda we are also working on a number of products in various stages of development for which applications have not yet been filed top related linksfuture directions technology innovation pipeline generics division factglobal pharmaceuticals currently markets  generic pharmaceutical products which represent dosage variations of  different pharmaceutical compounds copyright   impax laboratories inc all rights reserved privacy policy legal notices purchase order terms and conditions sitemap home  global pharmaceuticals investor relations news careers contact impax laboratories global pharmaceuticals home about us products customers latest news mon  jul impax announces fda approval of its ab rated generic concerta® methylphenidate hydrochloride extendedrelease tablets ciiwed  jul impax announces fda approval and launch of additional strengths of generic focalin xr® dexmethylphenidate hydrochloride extendedrelease capsules ciithu  jun impax to report second quarter  results on august  view all products global offers a broad range of therapeutic generic products products featured product epinephrine injection usp autoinjector dosage  mg and  mg link to prescribing information including all warnings view product copyright   global pharmaceuticals all rights reserved home contact privacy policy legal notices sitemap contact  global pharmaceuticals investor relations news careers contact impax laboratories global pharmaceuticals home about us products customers home » contact contact impax laboratories inc 6 office center drive suite  fort washington pa 4 telephone  4                     46 fax contracts 55 customer service  orders  returns email contracts contractsglobalpharcom customer service customerservicegroupglobalpharcom to report suspected adverse reactions product complaints or for medical information please contact phone impax 46 option  phone 5 46 option       or email inquiriesimpaxlabscom      or 47 genstar road hayward ca 44 attention medical affairs you are encouraged to report negative side effects of prescription drugs to the fda visit wwwfdagovmedwatch or call fda for customer service related questions product orders delivery billing account etc please contact phone impax 46 option      or email customerservicegroupglobalpharcom for investor information email investimpaxlabscom for business development please visit business development page global pharma factour generics division currently manufactures and markets  generic pharmaceutical products which represent dosage variations of  different pharmaceutical compounds copyright   global pharmaceuticals all rights reserved home contact privacy policy legal notices sitemap microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext74 about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext7475 where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext7476 personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext747 personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext747 personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext74 legal privacy  cookies   microsoft allergan  leading growth pharma  allergan homehomeinvestorsinvestorsnewsnewsevents  presentationsevents  presentationsinvestor faqsinvestor faqsanalysts coverageanalysts coveragestock informationstock informationma activitiesma activitiescorporate governancecorporate governanceshareholder servicesshareholder servicesfinancial informationfinancial informationproductsproductswhat we treatwhat we treatkey productskey productsdrug safetydrug safetyqualityqualitypatent noticespatent noticesmedical informationmedical informationr  dr  dwe live open sciencewe live open sciencerd areas of focusrd areas of focusallergan pipelineallergan pipelineclinical trialsclinical trialsaboutaboutcompany profilecompany profileexecutive leadershipexecutive leadershipglobal footprintglobal footprintglobal locationsglobal locationscontactcontactresponsibilityresponsibilitysocial contractsocial contractsocial responsibilitysocial responsibilityallergan foundationallergan foundationcalifornia supply chain disclosurecalifornia supply chain disclosurealliance support and ime grantsalliance support and ime grantshealth care provider partnerships  paymentshealth care provider partnerships  paymentspatient resourcespatient resourcespatient safety  product qualitypatient safety  product qualityphysician resourcesphysician resourcesanimal testinganimal testingnewsnewspress releasespress releasesmedia contactsmedia contactsnewsroomnewsroomcareerscareerscareer opportunitiescareer opportunitiesworking at allerganworking at allerganuniversity recruitinguniversity recruitingveteransveterans home  investors  read the full story allergan acquisition investor information news events  presentations investor faqs analysts coverage stock information stock chart  quote historical price lookup investment calculator ma activities allergan acquisition forest laboratories acquisition warner chilcott acquisition teva agreement corporate governance executive officers and directors committee composition committee charters code of conduct governance guidelines insider transactions allergan compliance program memorandum of association shareholder services information requests investor kit email alerts dividends financial information sec filings annual reports quarterly results proxy materials corporate fact sheet products  what we treat key products our products product prescribing drug safety quality patent notices medical information medical information request r  d  we live open science rd areas of focus allergan pipeline clinical trials participating in an allergan clinical trial clinical trial results sharing post marketing commitments sharing patientlevel data clinical trials investigators investigator initiated trials about  learn more a global growth pharma leader company profile executive leadership global footprint pharmaceuticals business development global locations commercial operations supply chain countries contact responsibility  learn more high priorities sustainability  continual improvement social contract social responsibility environmental employees facilities  manufacturing partners community public policy allergan foundation california supply chain disclosure alliance support and ime grants alliance support independent medical education grants patient resources patient assistance programs patient safety  product quality research and development risks and benefits quality physician resources animal testing news  ceo blog press releases media contacts newsroom allergan images allergan logos company profile executive bios  photos careers  career opportunities working at allergan our employees university recruiting internship  coops fellowship programs veterans go our employees i am bold for life caitlin sandahl read more news 77  products allergan’s truberzi®▼ eluxadoline receives positive  7  investors joseph h boccuzi appointed to allergan plc board of  see all news  ceo blog 7 building a consensus on medical aesthetic treatment for minors 6 helping our daughters stick with stem science technology engineering  math see all blog posts  stock quote refresh quote exchange volume country websites global corporate website africa south africa egypt americas argentina barbados bolivia brazil canada chile colombia costa rica dominican republic ecuador el salvador guatemala honduras jamaica mexico panama peru puerto rico trinidad  tobago uruguay venezuela asia pacific australia bahrain bangladesh china hong kong india indonesia israel japan jordan korea kuwait lebanon malaysia new zealand pakistan palestine philippines russia saudi arabia sri lanka singapore taiwan thailand united arab emirates vietnam yemen europe austria belgium bulgaria czech republic denmark estonia finland france germany greece hungary ireland italy latvia lithuania malta netherlands norway poland portugal romania serbia slovakia spain sweden switzerland turkey ukraine united kingdom global pharma labs inc  san leandro california ﻿ usa  sun pharmaceutical industries ltd skip to main content home business development product contact a a a print global presence africamorocco nigeria south africa asia pacificaustralia japan malaysia myanmar sri lanka europefrance germany ireland italy lithuania the netherlands poland romania spain united kingdom denmark finland hungary norway sweden north americacanada usa south americabrazil cisrussia ukraine affiliated websitestaro pharmaceutical industries limited dusa pharmaceuticals text size a a a usa tell a friend print home » usa products contact us the world’s largest pharmaceuticals market is also the biggest market for sun pharma we have been present in the us since  working with the country’s healthcare system with a focus on generics branded generics and overthecounter otc products we are valued suppliers to the largest wholesalers distributors warehousing and nonwarehousing chain drugstores and managed care providers being a vertically integrated company with a global presence we have the flexibility to develop and manufacture products in the us as well as at other locations across the world our us headquarters are in cranbury new jersey and we have distribution and customer service teams at multiple locations across the country sun pharma is present in the us through its own legal entities as well as its subsidiary taro pharmaceuticals over the last few years sun pharma has made several acquisitions in the us including caraco dusa pharmaceuticals and pharmalucence currently we are market leaders in the generic dermatology sector with a broad product portfolio for the treatment of actinic keratosis fungal infections and acne we have strong capabilities in developing complex products and have a robust pipeline of  andas including high value firsttofile ftf opportunities sun pharma’s latest acquisition of a majority interest in ranbaxy laboratories limited ranbaxy and its ohm laboratories facilities in the new jersey makes it the largest indian pharma company in the us market with a significantly expanded portfolio of lifesaving and enhancing medicines sun pharma and ranbaxy have similar backgrounds and corporate values with customeroriented cultures and researchdriven business models ranbaxy fits in well with sun pharma’s network of companies serving the us healthcare system we have built a strong reputation as a company that is market driven focused on customer service and capable of offering a wide range of affordable pharmaceutical products we continue to expand our product portfolio in the us market to the benefit of patients prescribers and other stakeholders in the healthcare system taro markets a broad range of prescription and otc products it is a leading manufacturer and supplier of topical dermatologicals  with a growing line of both topical products and solid dosage formulations mainly used in cardiology and neurology therapies dusa is focused on the development and marketing of dermatology products dusa’s flagship product levulan® photodynamic therapy pdt is a technology platform used in conjunction with its proprietary light source the bluu® blue light photodynamic therapy illuminator for the treatment of minimally to moderately thick actinic keratosis of the face or scalp pharmalucence is a manufacturer of noncytotoxic human injectable pharmaceuticals in either liquid or lyophilized form it also specialises in radio pharmaceutical products pharmalucence’s 7 sq ft manufacturing facility is the regions first unit to utilise fully automated and isolated aseptic technology in support of a wide array of needs from small clinical fills up to full commercial scale production for markets worldwide ohm laboratories is a manufacturer of prescription and otc drugs in solid dosage forms ohm is also approved to manufacture controlled substances by the us drug enforcement agency dea its stateoftheart laboratory manufacturing and warehousing facilities are capable of handling highvolume products and large batch sizes while its supply chain efficiency ensures seamless transportation to customer locations ohm is a frontrunner in bringing unique product deliveries and complex combinations to the market we provide highquality affordable medicines trusted by healthcare professionals and patients in over  countries of the world our presence in  key markets around the world is supported by  manufacturing facilities across five continents we have a multicultural workforce comprising more than  employees of over 5 nationalities patient assistance program in partnership with rx outreach sun pharma has launched a patient assistance program to learn more please click here healthcare compliance north america for more information on sun pharmaceutical industries incorporated compliance program please click here language english choose your region go to our usa site view asia excluding india view go to our europe site view india view middle east  africa view choose your country australia denmark finland france germany italy netherlands norway spain sweden uk usa global pharma labs inc  san leandro california